Drug Discovery & Delivery Core
Our experienced DDDC possess all the professional skills and knowledgebase required to undertake essential drug discovery and delivery programs to drive them from target validation, through hit identification, hit-to-lead determination and lead optimization to develop a high-quality and well-characterized drug candidate (Fig. 1).
Fig. 1. DDD Core workflow and services (Aim 1) utilized to discover and develop validated and well-characterized drug candidates to support research projects and a sustainable core.
We offer screening approaches to identify hit compounds, including fragment-based screens, peptide-based drug screening, high-throughput screening and complementary in silico approaches.
We provide hit-to-lead services where high-throughput chemistry enables the rapid design and synthesis of libraries of novel compounds. Successive use of in silico techniques and medicinal chemistry, enables our team to produce high quality leads for further optimization.
We will develop in house solutions to deliver robust data for complex projects to fit your needs. Our solutions include a broad range of biophysical, biochemical, cellular and live cell imaging platforms as well as translational assays. We integrate early ADMETox profiling, PK/PD correlations, to predict optimal human dose.
Target Validation and Structure Optimization
- Hit Identification and/or Virtual Screening (transcriptomic screens and structural docking screens)
- Bulk and Single Cell RNA Sequencing and Bioinformatics Analysis
- Screening with Virtual Combinatorial Peptide Library
- Lead Optimizations
- Fragment-based drug discovery
- Structure-based drug discovery
- Chemical Synthesis
- ADMETox Assessment including perilymph collection and analysis
- Drug dosage form design
- Zebrafish screens in vivo
Fig. 2. Pipelines for screening and validation of small molecule or peptide hits in DDD CORE.
Our synthetic organic/medicinal chemists work closely with computational chemistry, bioscience and drug metabolism/pharmacokinetics (DMPK) teams to assemble a project-specific iterative drug discovery process that addresses key challenges at each stage of the project. Our close proximity and state of the art bioinformatics system allows a very rapid design-synthesize-test-analyze cycle to efficiently inform decision making.
The engine driving most small molecule discovery programs is the chemistry team.
A journey towards a successful product launch initiates with high quality research integration within different disciplines. At DDDC, we have developed an international reputation at Creighton University in the field of medicinal chemistry with a strong track record of delivering clinical candidates. Our highly trained team of chemists are hand-picked from across the globe with the singular goal of bringing their experience to tackle most difficult synthetic challenges.
Our perfect mix of experience scientist includes research-staff with top notch expertise of progressing compounds from concept-to-lead-to-new chemical entity-to market; they provide appropriate support and guidance in the pursuit of our internal/external client’s goals, and continuous mentorship and training for the next generation of budding drug discovery scientist/research scholars. We value our clients and provide professional service with the aim that customers return to our medicinal chemistry facilities, again and again, to take advantage of our wide-ranging expertise and ability to conduct a hypothesis-driven approach with rapid data generation.
Our proficiency in library synthesis and scaffold design allows rapid access to many compounds for Structure Activity Relationships (SAR) evaluation.
Our easy access to database and analytical software allows our scientists to analyze data, identify trends and provide support for informed selection of the next synthetic targets.
Our experienced team provide early determination and assessment of critical ADMETox properties to guide lead discovery with goals of identifying well characterized drug candidates.
We have broad experiences in prodrug technology platforms, such as time- and pH-release driven strategies, while optimizing stability and solubility of the parent compound(s).
Innovative and robust chemical synthesis is essential when seeking to generate novel patentable molecules with optimized biochemical profile.
When you have a dedicated team by your side capable of efficiently bringing your concepts and ideas to problem can make all the difference on handling synthetic challenges. Here at DDDC we are proud to have cultivated most dynamic synthetic chemistry group combining industry- and academia-based ideologies.
Our highly trained team of chemists are qualified to PhD level or higher. Each has been hand-picked from across the globe with the singular goal of bringing their experience to tackle most difficult synthetic challenges.
Solid phase peptide synthesis of polypeptides at 0.25 mmol scale using a microwave-assisted automated peptide synthesizer.
Fig. 3. Inhibition of protein-protein interaction resulted in cell death. Virtual combinatorial tetrapeptide library was docked, using our GPU-cluster (A), on the dimerization interface 14-3-3 protein (B). The best binder peptide was chemically synthesized using our microwave peptide synthesizer (C) and promoted the apoptosis of skin cancer (Lovas, unpublished results and patent application).
When the experimental three-dimensional structure of a target protein is not available, the structure is determined by homology modeling and refined by subsequent molecular dynamics (MD) simulations to be appropriate for docking simulations.
We have maintained highly efficient and most accurate analytical services for providing full confidence in the structure and purity of our molecules.
High quality synthetic and medicinal chemistry requires high quality analytical chemistry support. Having confidence in the structural characterization of your compounds is vital and allows efficient progression of a lead series. At DDDC we have invested heavily in the latest analytical tools to facilitate this process.
Fig. 4. A) AB Sciex QTrap 5500 mass spectrometer used for quantification experiments (ADME and PK/PD). B) Example chromatogram with resolved novel antitubercular (North 2) and internal standard (warfarin) monitored through specific mass transitions.
DDDC Laboratories are equipped with fume hoods and sophisticated instrumentation, provide protein conjugations, multi-step chemical synthesis from milligram- to multigram scale.
Our in-house equipment currently is listed in Table 1 (with their locations) that includes:
- AB Sciex QTrap 5500 mass spectrometer (Fig. 4)
- Q Exactive Hybrid Quadrupole-Orbitrap™ Mass Spectrometer with Microflow UHPLC Systems
- UltrafleXtreme MALDI-MS System from Bruker
- 10XGenomics (Fig. 5)
- Zebrafish facilities (Fig. 6)
- 400-MHz NMR spectrometers
- Waters Synapt-G1 Q-TOF
- Agilent 1200s and Waters Acquity LC systems
- Preparative HPLC systems
- UPLC system (to be purchased)
- Hydrogen generator (to be verified)
- Combi-flash purification systems
- ion chromatography system
- Several flow reactors
- High-pressure autoclaves
- Electrochemistry Kit (to be verified)
- Multi-Scale Peptide Synthesizer (Dr Lovas)
- KF Titrator (to be verified)
- Labconco lyophilizer (Dr Jadhav Lab)
- -80℃ freezer
- Mettler Toledo ventilated weighing enclosure
- Liquid nitrogen storage
- High throughput chemistry
Fig. 5. Single cell RNA seq results using 10x Genomics in the DDD Core. Top: Single cell suspensions are loaded onto the Chromium Controller. Bottom: Ordering of different mouse E10 forebrain cells (individual dots) along the pseudotime trajectory (collaboration with a Center Investigator).
DDDC offers series of DMPK consultancy services to drug discovery research teams within (but not limited to) the academic sector. We can work as a stand-alone function or as an integral part of the drug discovery project team based on the expertise requirements from the clients.
- DMPK consultancy from Hit ID right through to Candidate Nomination.
- Strength in providing DMPK input into hearing discovery projects.
- Independent expert DMPK reviews of ongoing discovery projects.
- Expertise in integrating DMPK into early drug discovery.
- Problem-solving abilities around ADME and PK.
- Auditing of DMPK of third party (e.g CRO) reports.
- Review and unbiased critique of research proposals.
- Third party negotiations on DMPK packages for in-licensing opportunities.
- Physicochemical profiling
- IVIVE and human PK predictions
- In vitro ADME
- In vivo PK/PD
- Metabolite identification
Fig. 6. Drug Discovery & Delivery Core (DDD Core), Zebrafish Facility. A: ZEBTEC Zebrafish Housing system (Tecniplast, stand-alone unit), can hold up to 1,250 adult zebrafish. A’: ZebraLab & ZebraBox turnkey for PPI (Viewpoint Life Sciences) and Vestibular optokiometric response system (VOR). B-D: 5dpf zebrafish were incubated with vehicle alone (B), cisplatin alone (400µM, C) and cisplatin + dabrafenib (D). Fish were fixed and immunostained for GFP (green) and otoferlin (red).
Our in-depth knowledge of target biology, therapeutic area specialism, and experience of working collaboratively at each stage of the drug discovery pipeline allows the efficient design and implementation of tailored high-quality assays, which help to accelerate your drug discovery programs.
- Bulk and single cell RNA sequencing using 10XGenomics platform and subsequent bioinformatics analysis
- Assay development
- Understanding the assay purpose
- Identifying different assay formats
- Developing or sourcing optimal assay reagents
- Monitoring assay performance
- Options for automation and scaling
- Quality control via statistical validation
- Fig: typical hit identification hit screening cascade (refer grant)
- Cellular assays
- Biochemical assays
- Biophysical assays
|Director: Dr. Jian Zuo, PhD will lead the DDDC. Dr. Zuo is currently Chair and Professor of Biomedical Sciences in School of Medicine at Creighton University, and has made significant contributions to drug screening and initial validation of candidate therapeutics in the inner ear. He has currently two NIH R01 grants, one of which emphasizes on drug discovery for CDK2 inhibitors for cisplatin-induced hearing loss (CIHL) and NIHL. Additionally, he has three DoD R01-level grant awards on drug development for hearing regeneration. He is a co-Founder of Ting Therapeutics that recently obtained three NIH SBIR phase I Awards to develop ototherapuetics.|
|Co-Director: Dr. Sandor Lovas, PhD is a Professor in the Department of Biomedical Sciences in School of Medicine at Creighton University. He has a long-time track record in studying conformation-biological activity relationships of polypeptides, in silico designing polypeptides for various targets and studying polypeptide structure. He is a PI of a large, six-year, state-supported, LB595 Cancer Center grant award.|
|Core Manager: Dr. Gopal Jadhav, MBA, PhD is an Assistant Professor (tenure-track) in the Department of Pharmacology and Neuroscience in School of Medicine at Creighton University. He is a medicinal chemist with experience in the pharmaceutical industry and academic research, He has been engaged in the full spectrum of drug discovery programs – from hit to lead libraries, hit-to-lead campaigns, all the way to successful lead optimization projects and candidate drug selection.|
News and Events
Stay tuned for Core updates!
Director: Dr. Jian Zuo jianzuo [at] creighton [dot] edu
Co-Director: Dr. Jeff North jeffreynorth [at] creighton [dot] edu
Co-Director: Dr. Sandor Lovas sandorlovas [at] creighton [dot] edu
Core Manager: Dr. Gopal Jadhav gopaljadhav [at] creighton [dot] edu